Cellectis (CLLS) Set to Release Earnings on Friday

Key Points

• Cellectis is expected to report Q3 2026 results after Friday’s market close, with analysts forecasting a loss of $0.18 per share and revenue of $15.61 million.
• In its previous quarter, the company reported a $0.22-per-share loss, better than estimates, but revenue of $6.90 million fell short of forecasts of $11.05 million.
• Shares have fallen sharply, and analyst sentiment is mixed: the consensus rating is “Hold” with an average price target of $5.46, while recent firms have cut ratings or targets.

Cellectis (NASDAQ:CLLS - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Friday, November 13th. Analysts expect Cellectis to post earnings of ($0.18) per share and revenue of $15.61 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 3:00 AM ET.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.

Cellectis Trading Down 12.0%

Shares of NASDAQ CLLS opened at $1.03 on Friday. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37. The stock has a market capitalization of $103.35 million, a P/E ratio of -1.58 and a beta of 3.21. Cellectis has a 1-year low of $0.88 and a 1-year high of $5.45. The business has a fifty day moving average price of $1.71 and a 200 day moving average price of $3.01.

Analyst Ratings Changes

CLLS has been the topic of several analyst reports. Citizens Jmp lowered Cellectis from an "outperform" rating to a "market perform" rating in a research note on Tuesday, September 15th. Barclays downgraded shares of Cellectis from an "overweight" rating to an "underweight" rating and reduced their target price for the stock from $9.00 to $1.30 in a report on Wednesday, September 16th. Wells Fargo & Company decreased their price target on shares of Cellectis from $4.00 to $3.00 and set an "equal weight" rating for the company in a research report on Tuesday, September 15th. Weiss Ratings upgraded shares of Cellectis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 2nd. Finally, Robert W. Baird lowered their price target on shares of Cellectis from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $5.46.

About Cellectis

Cellectis SA is a biotechnology company focused on developing gene-edited cell therapies for the treatment of cancer and other serious diseases. Founded in France in 1999, the company pioneered the use of TALEN gene-editing technology to modify immune cells and develop off-the-shelf, or allogeneic, treatments.

The company's primary programs involve genetically modified T cells, including its UCART platform of allogeneic chimeric antigen receptor T-cell therapies. These products are designed to target specific cancer antigens and are being investigated in clinical studies for hematologic malignancies and other cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.